Akari Therapeutics

Focus: Akari Therapeutics is a Boston-based biotechnology company focused on novel anti-inflammatory, first-in-class synthetic drugs in immunology. The company operates as a clinical-stage biotech with a pipeline spanning rare and inflammatory diseases.

Immunology

Profile data last refreshed Yesterday · AI intelligence enriched 2w ago

Open Jobs

About Akari Therapeutics

AI assessmentNot Hiring

No open roles listed right now. Follow Akari Therapeutics to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthSolid

Pipeline

Mid-stage

1 Phase 3+

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

The CASCADE Study - Measures of Complement Activation and Inflammation in Patients With Covid-19

Coronavirus

N/A

Clinical Trials (1)

NCT04453527The CASCADE Study - Measures of Complement Activation and Inflammation in Patients With Covid-19

N/A

Help build intelligence for Akari Therapeutics

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Advancing Phase 3 program (rVA576) in rare disease with 6 active trials suggesting significant clinical validation and near-term catalyst potential
First-in-class focus in anti-inflammatory space represents opportunity to work on differentiated mechanisms with limited competitive exposure
Immunology specialization aligns with high-growth therapeutic area with sustained industry investment and long-term career relevance

Watch Out For

Zero active job openings signals minimal hiring, suggesting limited entry points and potential resource constraints
Pre-revenue biotech status with undisclosed funding creates cash runway uncertainty and restructuring risk if Phase 3 trials underperform

Generated by Claude from Akari Therapeutics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

MRX-6

Atopic Dermatitis

Phase 2

Clinical Trials (1)

NCT02031445Double-Blind, Trial to Evaluate the Safety and Efficacy of MRX-6 Cream 2%

Phase 2

coversin

Paroxysmal Nocturnal Hemoglobinuria

Phase 2

Clinical Trials (2)

NCT03427060Coversin in PNH in Patients With Resistance to Eculizumab Due to Complement C5 Polymorphisms

Phase 2

NCT02591862Coversin in Paroxysmal Nocturnal Haemoglobinuria (PNH)

Phase 2

rVA576

Paroxysmal Nocturnal Hemoglobinuria

Phase 3

Clinical Trials (5)

NCT05061771Nomacopan Therapy in Adult Patients With Bullous Pemphigoid Receiving Adjunct Oral Corticosteroid Therapy (ARREST-BP)

Phase 3

NCT04784455Nomacopan (rVA576) in Transplant Associated Thrombotic Microangiopathy

Phase 3

NCT03829449rVA576 (Coversin) Long Term Safety and Efficacy Surveillance Study

Phase 3

+2 more

Open Jobs (0)

No open positions listed yet. Check their careers page directly.

Interview Prep Quick Facts

Portfolio: 10 clinical trials

Top TAs: Immunology

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo

Therapeutic Area Focus

Immunology

1 pipeline

Marketed

Pipeline